Challenging a Misnomer? The Role of Inflammatory Pathways in Inflammatory Breast Cancer

Table 2

Recent recruiting trials in IBC. T, tumor stage; N, nodal; FEC, fluorouracil epirubucin cyclophosphamide; pCR, pathological complete response; MTD, maximum tolerated dose; PFS, progression-free survival; DCR, disease control rate; PD, progressive disease.

Trial name	Study population	Phase	Study target	Treatment arms	Primary outcome
NCT01880385	T4d, any N stage, IBC	I	30	Open-label neoadjuvant bevacizumab + FEC followed by adjuvant docetaxel (+/−trastuzumab in HER2 positive) and RT	pCR
NCT02623972	HER2-negative, locally advanced IBC	II	25	Neoadjuvant eribulin followed by doxorubicin and cyclophosphamide	pCR
NCT01938833	Metastatic, HER2-negative IBC	I/II	47	Romidepsin and Nab-paclitaxel until PD; or unacceptable toxicity	MTD and PFS
NCT02389764	Metastatic, HER2-negative IBC	II	44	Oral nintedanib	CBR
NCT00820547	T4d, any N (stage IIIB or IIIC), HER2-negative IBC	II	100	Neoadjuvant FEC + bevacizumab followed by adjuvant docetaxel + 12 months bevacizumab	pCR
NCT02411656	HER2-negative, metastatic IBC or recurrent disease after treated primary	II	35	Adjuvant pembrolizumab for up to 24 months	DCR
NCT01036087	HER2-negative, locally advanced IBC	II	40	Neoadjuvant panitumumab + nab-paclitaxel + carboplatin + FEC	pCR
NCT01796197	Nonmetastatic, HER2-positive IBC	II	30	Preoperative trastuzumab + pertuzumab; + paclitaxel followed by adjuvant trastuzumab + pertuzumab +/− AC	pCR
NCT02041429	Unresectable or metastatic triple-negative IBC	I/II	24	Preoperative ruxolitinib + paclitaxel	MTD
NCT01525966	Locally advanced, triple-negative IBC (also open in non-IBC)	II	69	Preoperative carboplatin and paclitaxel; (albumin-stabilized nanoparticle)	pCR